remsss

Remdesivir cuts death risk by 62% in coronavirus patients, new study shows

pharmafile | July 13, 2020 | News story | Sales and Marketing COVID-19, coronavirus 

Gilead’s remdesivir reduced the risk of death in 62% of severe COVID-19 patients, according to a new study.

The company released a statement which said: “The analysis demonstrated that remdesivir treatment was associated with the significantly improved clinical recovery and a 62 percent reduction in the risk of mortality compared to standard of care.” 

This latest Phase 3 SIMPLE trial included 312 patients being treated with Gilead’s drug compared with 818 being in the standard care group with both groups showing a similar severity of the virus.

Advertisement

74.4% of the remdesivir group recovered by day 14, versus 59% of the standard care group. It also showed that 7.6% of the group being treated with the drug died compared to 12.5% of the care group meaning it cut the death risk by 62%. Gilead also stated that its compassionate use program demonstrated that 83% of 77 pediatric patients and 92% of 86 pregnant and postpartum women recovered from the virus by day 28.

South Korea has started to provide the treatment free of charge through the Ministry of Food and Drug Safety’s special import program. However, from August patients will have to pay the medical costs.

Conor Kavanagh

Related Content

covid_cell

COVID-19 vaccine eligibility creates challenges for UK pharmacies

Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …

Prescriptions image

Mental health medicine use in England reaches record high, NHSBSA report reveals

According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …

Vaccine image

FDA approves Moderna’s Spikevax for children at increased risk of COVID-19

Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, …

The Gateway to Local Adoption Series

Latest content